International Delegate Committee

Trish Flanagan is a co-founding board member and President of YBRP.  Trish is a seasoned Early Childhood Educator and earned her Bachelors Degree of Science from Penn State University majoring in Human Development and Family Studies with an Early Childhood focus.  Trish is dedicated to the Yellow Brick Road Project's mission and improving the life of her daughter, Morgan, and others touched by an HNRNPH2 mutation.

Paula Cole Tyson is a dedicated co-founding member of the Project and devoted mother to Lillie, a beautiful little girl impacted by an HNRNPH2 genetic variation. She is currently a Compensation Consultant and Analyst at ChaseCompGroup.  Before joining the firm in 2011, she worked independently for consulting and other service firms, assisting in client relations, account management, and accounting functions.  Prior to her independent work, she worked for a private company for six years in personnel management and client relations and began her career as an analyst and consultant for Watson Wyatt (now Towers Watson) in the areas of human resources and organization effectiveness.  She obtained her Bachelor’s degree in Romance Languages from the University of Georgia, graduating Magna Cum Laude.

Nicole Glenn is the West Coast delegate of the Yellow Brick Road Project and mother to Rose (Rosie), a tenacious three-year-old touched by the HNRNPH2 mutation. Nicole is dedicated to improving the lives of all children through her pediatric practice, and thanks to Rosie, wants to further help all children affected by HNRNPH2. She earned her bachelor’s degree in Physiology at the University of Colorado, Boulder and her medical degree at Rush University in Chicago. She completed her Pediatric Residency at Stanford Children’s Health Lucile Packard and practices General Pediatrics with the Palo Alto Medical Foundation in Northern California. As the West Coast Delegate, she’s determined to raise awareness for children living with HNRNPH2, advocate for their special needs as well as provide support for the families of these amazing kids.

Stacy Paddon is determined to help her daughter Cady and all those affected by HNRNPH2 mutations to live the best lives they can. She currently works for the Business Intelligence team at Christie's auction house in London, having previously spent time in the company's Human Resources office where she managed European recruitment. She has previously held management positions at the National Trust, the Vancouver 2010 Olympic and Paralympic Winter Games Organizing Committee and ING Insurance. She holds a Bachelor of Journalism degree from Carleton University with Combined Honours in Political Science and is a Chartered Insurance Professional.

Alana works part-time as an Admissions Officer for Aged Care.  She connects with families and hospitals to support the elderly transitioning into residential care. 

Prior to this, Alana had strong Marketing background with several Real Estate companies spanning over 10 years. 

She also is an active Mum for Isla’s younger twin brothers, who are 2 years old.

Tanya is a busy mom of 3, working part time as an office administrator in a small town in Manitoba, where she grew up. Before that she was a dental assistant for 2 years. Her middle child Emily is one of the few children affected with HNRNPH2. After receiving Emily’s diagnosis, Tanya was eager to find out more about HNRNPH2 and meet others with this condition. 

Vera Udovichenko (Makarova) from Russia, Moscow is a happy mom to two sweet boys - the younger one, Boris, is touched by the HNRNPH2 mutation and is one of the few boys with this condition. Vera works as a web-editor for business school, speaks three languages - Russian, English and French - and runs a blog about her son and his diagnosis in Telegram.

Kaori Suzuki is the mother of Nozomi, a little girl with the HNRNPH2 mutation. She is determined to raise awareness of HNRNPH2 and find other patients in Japan. She graduated from Ritsumeikan University with a degree in Industrial Sociology and she has been working for a pharmaceutical company since 2006.